Sugi Predict

Sugi Predict / Compounds / SCHEMBL2463514

SCHEMBL2463514

SCHEMBL2463514

CC(C)NCC1CC(C2=C3C=NC=C[N+]3(N)C(c3cccc(OCc4ccccc4)c3)=N2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 17/20 0.50
▸ TNK2 Q07912 1/20 0.38
▸ INSR P06213 4/20 0.35
▸ ROCK2 O75116 3/20 0.35
▸ LYN P07948 3/20 0.35
▸ RET P07949 3/20 0.35
▸ PTK6 Q13882 3/20 0.35
▸ MAP4K5 Q9Y4K4 3/20 0.35
▸ PRKD3 O94806 2/20 0.35
▸ FGFR1 P11362 2/20 0.35
▸ RPS6KB1 P23443 2/20 0.35
▸ FLT4 P35916 2/20 0.35
▸ FLT3 P36888 2/20 0.35
▸ FRK P42685 2/20 0.35
▸ STK3 Q13188 2/20 0.35
▸ ROCK1 Q13464 2/20 0.35
▸ ERBB4 Q15303 2/20 0.35
▸ AURKB Q96GD4 2/20 0.35
▸ PRKD2 Q9BZL6 2/20 0.35
▸ MKNK2 Q9HBH9 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2463405 0.93 IGF1R (0.44) IGF1RTNK2ALOX5
SCHEMBL2460659 0.89 IGF1R (0.47) IGF1RTNK2INSRROCK2LYN
SCHEMBL2457528 0.89 IGF1R (0.39) IGF1RTNK2INSRROCK2LYN
SCHEMBL2460490 0.89 IGF1R (0.39) IGF1RTNK2INSRROCK2LYN
SCHEMBL2463565 0.88 IGF1R (0.38) IGF1RTNK2INSRROCK2LYN
SCHEMBL2458151 0.87 IGF1R (0.38) IGF1RTNK2INSRROCK2LYN
SCHEMBL2461856 0.87 IGF1R (0.39) IGF1RTNK2INSRROCK2LYN
SCHEMBL2459711 0.87 IGF1R (0.41) IGF1RTNK2INSRROCK2LYN
SCHEMBL2457195 0.86 IGF1R (0.38) IGF1RTNK2INSRROCK2LYN
SCHEMBL2460547 0.86 IGF1R (0.48) IGF1RTNK2INSRROCK2LYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885INSR 5/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885INSR 5/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885INSR 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.